Benefits
Lipid profile improvement in postmenopausal women
A randomized trial of postmenopausal women on 20, 30, or 50 mg/day for 24 weeks reported improvements in lipid markers and bone turnover, including HDL-cholesterol increased ~34%. The lipid signal is among the most consistent findings across the trials.
Bone turnover marker improvement
Reductions in bone resorption markers (urinary deoxypyridinoline) and increases in bone formation markers were reported in postmenopausal women on 20-50 mg/day for 24 weeks. Long-term DXA bone density outcomes have not been established — current evidence is on biochemical markers rather than fracture-relevant endpoints.
Climacteric/menopausal symptom relief
An open-label pilot in perimenopausal women on 50-100 mg/day for 6 months reported improvements in vasomotor symptoms (hot flashes, night sweats), mood, and vaginal dryness. The trial was uncontrolled and signals require confirmation in larger placebo-controlled studies.
Possible breast/endometrial selectivity (mechanistic)
Miroestrol shows SERM-like (selective estrogen receptor modulator) characteristics in preclinical work — competing with endogenous estrogen at receptors and potentially reducing rather than amplifying mitogenic signaling in some tissues. This is preclinical mechanism — clinical safety in breast/endometrial tissue requires the explicit contraindication noted in the safety section.
Skin and rejuvenation traditional use
Traditional use in Thailand emphasizes skin elasticity, breast firmness, and youthful appearance. Some emerging cosmeceutical interest based on phytoestrogen activity at skin estrogen receptors. Clinical evidence on skin endpoints specifically is limited.
Mechanism of action
Estrogen receptor activation via miroestrol
Miroestrol (chromene-class phytoestrogen, also present in trace amounts in Butea superba) is structurally similar to estradiol and activates both ERα and ERβ. Estimated potency is ~50× soy isoflavone genistein. Deoxymiroestrol is the more abundant precursor and is converted to miroestrol. Other components include daidzein, genistein, puerarin, and kwakhurin.
SERM-like tissue selectivity (preclinical)
Selective Estrogen Receptor Modulator-like behavior in preclinical models — competes with endogenous estrogen at receptors, with tissue-specific agonist or antagonist behavior. The hypothesis underlies some safety positioning, but does not eliminate the contraindication in hormone-sensitive cancers.
Bone formation/resorption modulation
Estrogen receptor activation modulates osteoblast and osteoclast activity. Changes in bone turnover markers (deoxypyridinoline, osteocalcin) are consistent with the estrogen receptor mechanism.
Lipid metabolism via ERα-mediated transcription
Estrogen receptor alpha activation in liver modulates LDL receptor expression and HDL particle formation. This is the proposed mechanism for the lipid-improvement effects observed in trials.
Clinical trials
Clinical evidence on Pueraria Mirifica (Kwao Kruea Khao) for the indications and outcomes described.
postmenopausal women
Manonai J et al. 2008, Menopause 15(3):530-535. Randomized double-blind 3-arm dose-finding trial — postmenopausal women on 20, 30, or 50 mg/day Pueraria mirifica for 24 weeks. Reported improvements in lipid markers and bone turnover markers across doses. Foundational dose-response evidence for the ingredient.
Clinical evidence on Pueraria Mirifica (Kwao Kruea Khao) for the indications and outcomes described.
postmenopausal women
Okamura S et al. 2008. Reported HDL-cholesterol increased ~34% in postmenopausal women on Pueraria mirifica supplementation. The HDL-elevation magnitude is notable; replication and longer-term cardiovascular endpoint data would strengthen the rating.
Clinical evidence on Pueraria Mirifica (Kwao Kruea Khao) for the indications and outcomes described.
Clinical population described in trial publication.
Lamlertkittikul S,. Open-label pilot, perimenopausal women, 50-100 mg/day Pueraria mirifica root powder for 6 months. Reported improvements in vasomotor symptoms, mood, and vaginal dryness. Open-label and uncontrolled — preliminary evidence only.